{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:06:41Z","timestamp":1779527201466,"version":"3.53.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ymthe.2025.08.027","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T08:58:34Z","timestamp":1755766714000},"page":"5505-5515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-4134","authenticated-orcid":false,"given":"Jaime R.","family":"Merchan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shree","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Accomando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rodriguez-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deukwoo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia Roos","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Yavrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Ostertag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.027_bib1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.mt.6300054","article-title":"Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines","volume":"15","author":"Dalba","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41417-021-00331-7","article-title":"Vector engineering, strategies and targets in cancer gene therapy","volume":"29","author":"Singh","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","article-title":"Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer","volume":"21","author":"Collins","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/neuonc\/nor199","article-title":"Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector","volume":"14","author":"Ostertag","year":"2012","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/mt.2012.83","article-title":"Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression","volume":"20","author":"Perez","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hum.2014.100","article-title":"Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model","volume":"26","author":"Huang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2017.12.001","article-title":"A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models","volume":"8","author":"Yagiz","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.08.027_bib8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/neuonc\/nox037","article-title":"Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model","volume":"19","author":"Mitchell","year":"2017","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.662331","article-title":"Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges","volume":"8","author":"Yoder","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2025.08.027_bib12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/v13081528","article-title":"Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives","volume":"13","author":"Labbe","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.08.027_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-12-386509-0.00011-9","article-title":"Retroviral replicating vectors in cancer","volume":"507","author":"Logg","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.cgt.7700521","article-title":"Replicative retroviral vectors for cancer gene therapy","volume":"10","author":"Solly","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13543784.2019.1572112","article-title":"Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma","volume":"28","author":"Philbrick","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2025.08.027_bib16","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/neuonc\/now089","article-title":"Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models","volume":"18","author":"Yagiz","year":"2016","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3892\/mco.2021.2348","article-title":"Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review","volume":"15","author":"Morse","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2018.12.005","article-title":"A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer","volume":"12","author":"Chawla","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.08.027_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40291-016-0229-9","article-title":"Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies","volume":"20","author":"Mohanlal","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib20","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-18-0619","article-title":"Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients","volume":"24","author":"Hogan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.08.027_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005007","article-title":"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors","volume":"11","author":"Rudin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.08.027_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.08.027_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-21-0171","article-title":"Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients","volume":"10","author":"Samson","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.08.027_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.08.027_bib26","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.4049\/jimmunol.2001334","article-title":"Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells","volume":"207","author":"Vick","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.08.027_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41417-024-00810-7","article-title":"Therapeutic activity of retroviral replicating vector-mediated gene therapy in combination with anti-PD-1 antibody in a murine pancreatic cancer model","volume":"31","author":"Niwa","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.08.027_bib28","series-title":"R: A Language and Environment for Statistical Computing","author":"Team","year":"2019"},{"key":"10.1016\/j.ymthe.2025.08.027_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v021.i12","article-title":"Reshaping Data with the reshape Package","volume":"21","author":"Wickham","year":"2007","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.ymthe.2025.08.027_bib30","first-page":"78","article-title":"Reshaping and aggregating data: an introduction to reshape package","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.027_bib31","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625006574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625006574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:26:25Z","timestamp":1779524785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625006574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525001625006574"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.027","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}